August 1, 2019
Eisai CFO Ryohei Yanagi Eisai’s first-quarter sales were virtually flat, barely remaining in positive territory with a 0.5% rise as continued growth of its major cancer drug Lenvima (lenvatinib) more than cancelled out one-off negatives, according to its earnings released...read more